

The world is racing to find safe and effective vaccines against COVID-19. And when we do, these vaccines must be made available to everyone who needs them regardless of nationality or wealth. This is the fastest way to end the pandemic. So we want to know: **do world leaders' actions move us closer to, or further from, an equitable outcome?** The Vaccine Access Test provides a framework to answer this question based on the following metrics:

- **Support for & Collaboration with ACT-A:** Has this company collaborated with or provided financial support?
- **Transparency & Knowledge Sharing:** Has the company committed to non-profit and/or tiered pricing? Does this company share relevant knowledge and data to enable widespread access?
- **Multilateral Leadership:** Has leadership expended political capital to motivate cooperation on equity?
- **Deals:** Each deal this company has made to secure promising COVID-19 vaccine candidates is scored individually based on a set of metrics for how well they advance equity.

Each metric is worth up to 3 points and Deal Scores can earn up to 6 points. **Johnson & Johnson can earn up to 15 points.**

METRIC	SCORE	RATIONALE
<b>ACT-A</b> 	2	COVAX signed a memorandum of understanding with Johnson & Johnson for 500 million doses of the Janssen candidate.
<b>Transparency &amp; Knowledge Sharing</b> 	2	J&J has committed to not-for-profit pricing that will apply to the emergency pandemic period. J&J has not committed to sharing knowledge but has engaged in tech transfers.
<b>Multilateral Leadership</b> 	1	J&J committed to the Global Access Communique, thereby committing to ensuring global access, enabling affordability for lower income countries, and supporting equitable distribution globally.
<b>Deal Score (average)</b>	1.7	J&J has completed 3 deals with countries, with an average Deal Score of 1.7.

## Total Score: 6.7 out of 15

Johnson & Johnson's actions so far have proven a dedication to equitable outcomes, but the company has a long way to go before it is advancing equity. J&J has shown its commitment by committing to not-for-profit pricing, supporting the ACT-A, and committing to the Global Access Communique.

J&J can improve its score by going beyond tech transfers and sharing relevant knowledge, intellectual property and data to enable wide scale production, distribution and use of vaccines, as outlined in the WHO's Solidarity Call to Action.

